Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAR-302-5018 in SCI Subjects With NDO
NCT03168828Phase 1Completed
- Sponsor
- TARIS Biomedical
- Start
- Apr 2017
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of trospium in neurogenic detrusor overactivity (NDO), sponsored by TARIS Biomedical. Primary endpoint: Safety of TAR-302-5018 (Adverse Events). Started Apr 2017; status: completed.
02
Drugs
trospium
03
Conditions
neurogenic detrusor overactivity (NDO)
Beyond the preview
Go deeper on NCT03168828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03168828.